Study: CBD Dosing Relieves Symptoms In Patients With Anxiety Disorders

COLORADO: The daily administration of CBD is associated with sustained symptomatic relief in patients diagnosed with anxiety disorders, according to the results of a case series published in The Permanente Journal.

Investigators at the University of Colorado, Denver and Colorado State University assessed the adjunctive use of low daily doses of CBD (typically 25mg capsules) over a three-month period in a cohort of patients diagnosed with either sleep or anxiety disorders.

Researchers reported that patients experienced a “mild improvement” in sleep scores, and a larger “more sustained response to anxiety.” They also reported that “CBD appears to be better tolerated than routine psychiatric medications.”

Authors acknowledged that the therapeutic doses used in the study were far lower than those typically associated with anxiolytic action in prior clinical trials.

They concluded: “Anxiety scores decreased fairly rapidly, and this decrease was sustained during the study period. … Randomized and controlled trials are needed to provide definitive clinical guidance.”


For more information, contact Paul Armentano, NORML Deputy Director, at: paul@norml.org. Full text of the study, “Cannabidiol in anxiety and sleep: A large case series,” appears in The Permanente Journal.

New Study: Children With Autism See Improvement After Treatment With Tikun Olam High-CBD, Low-THC Medical Cannabis

NEW YORK: Children with Autism Spectrum Disorder (ASD) see a “significant” improvement in symptoms and less reliance on other medications after treatment with Tikun Olam’s Avidekel™ medical cannabis, as confirmed by a new study published in Scientific Reports.

The two-year study, “Real Life Experience Of Medical Cannabis Treatment In Autism: Analysis Of Safety And Efficacy,” followed 188 children (average age: 13) diagnosed with ASD. The patients were treated with Tikun Olam’s high-CBD, low-THC medical cannabis strains, which have been specifically cultivated and shown to provide symptom relief for ASD and related conditions with minimal psychoactive effect.

At the study’s outset, the most common patient symptoms were restlessness (90.4%), rage attacks (79.8%), and agitation (78.7%). After six months of daily cannabis treatment at Tikun Olam clinics in Israel, 80.1% of patients reported improvement of their symptoms, with 30.1% reporting “significant” improvement. Other key findings include:

  • Of 27 patients who had epilepsy, 24 reported improved or disappearance of symptoms;
  • 34% of patients decreased other medications; and
  • 20% of patients stopped using antipsychotic medication.

“Autism is a leading condition of concern worldwide, so this study couldn’t have come at a better time,” says Dr. Annabelle Manalo, PhD, Tikun Olam’s Science Director. “The data shows that autism patients can improve their overall quality of life utilizing a high CBD strain, and most importantly, that young users can safely and effectively benefit from medical cannabis.”

“With this study, cannabis is shown to be an effective choice for parents looking for the safest and most neuroprotective treatment.”

Side effects to cannabis treatment were minimal, with the most common at six months reported as restlessness (6.6%), sleepiness (3.2%), psychoactive effect (3.2%).

Medical Schools Including Cannabis Content In Their Curriculum

PENNSYLVANIA: A growing percentage of colleges of pharmacy are instituting medical cannabis training as part of their curriculum, according to survey data published in the journal Currents in Pharmacy Teaching and Learning.

Researchers at the University of Pittsburgh contacted 140 US schools of pharmacy regarding whether they include medical cannabis-related topics in their curriculum. Among respondents, 62 percent reported that they had instituted some level of medical marijuana training, while 23 percent answered that they intended to incorporate the topic to their coursework within the next 12 months.

The study is the first inventory of medical schools with regard to the inclusion of medical cannabis-related topics to their curriculum.

According to a 2015 evaluation of student pharmacists’ attitudes, 90 percent of respondents indicated that they favored the inclusion of medical cannabis instruction to their curriculum.


For more information, contact Paul Armentano, NORML Deputy Director, at: paul@norml.org. Full text of the study, “Evaluation of medical marijuana topics in the PharmD curriculum: A national survey of schools and colleges of pharmacy,” appears in Currents in Pharmacy Teaching and Learning.

Study: Cannabis Use Associated With Reduced Risk Of Alcohol-Induced Pancreatitis

MASSACHUSETTS: Habitual alcohol consumers who also use cannabis are at less risk for either acute or chronic pancreatitis as compared to those who do not use the substance, according to clinical data published in the journal Alcoholism, Clinical and Experimental Research.

A team of investigators from the United States and Canada assessed the prevalence of alcohol-induced pancreatitis in a nationwide sample of heavy alcohol users. They reported that those subjects who concomitantly used cannabis possessed a significantly lower risk of pancreatitis as compared to those who did not.

“Our findings suggest a reduced incidence of only alcohol-associated pancreatitis with cannabis use,” authors concluded.

Separate research by the team previously reported that “risky alcohol drinking combined with cannabis use is associated with reduced prevalence of alcohol-associated gastritis in patients.” Alcoholic gastritis refers to inflammation or erosion of the stomach lining that is caused by excessive alcohol consumption.


For more information, contact Paul Armentano, NORML Deputy Director, at: paul@norml.org. Full text of the study, “Reduced risk of alcohol-induced pancreatitis with cannabis use,” appears in Alcoholism, Clinical and Experimental Research.

 

Long-Term Cannabis Use Associated With Lower BMI

ARIZONA: Lifetime cannabis exposure is associated with lower body mass index (BMI), according to longitudinal data published in the journal Psychosomatic Medicine.

Researchers from Arizona State University and the University of Pittsburgh assessed the association between long-term cannabis exposure and cardiometabolic risk factors in a cohort of 253 men. They reported that greater marijuana exposure was associated with lower BMI as well as lower cholesterol levels and other risk factors.

“Cannabis use is associated with lower BMI and lower BMI is related to lower levels of risk on other cardiometabolic risk factors,” they concluded.

The findings are consistent with those of prior studies concluding that cannabis exposure is associated with lower BMIlower rates of obesity, and fewer incidences of type 2 diabetes.


For more information, contact Paul Armentano, NORML Deputy Director, at: paul@norml.org. Full text of the study, “Associations between cannabis use and cardiometabolic risk factors: A longitudinal study of men,” appears in Psychosomatic Medicine.

 

Ohio Board Of Pharmacy Announces Fourth Week Statistics For MMJ Patient & Caregiver Registry

State_of_Ohio_Board_of_pharmacy_logo2C

OHIO: After accepting patient registrations for four weeks, the Ohio Medical Marijuana Control Program has 4,964 recommendations in the Patient and Caregiver Registry. Of those with a recommendation, 3,575 have activated their Registry Card.

The State of Ohio Board of Pharmacy will continue to provide weekly updates through December after which a monthly report will be available.

Case Report: Daily CBD Administration Associated With Remission Of Schizophrenic Symptoms

GERMANY: The adjunctive use of cannabidiol is associated with a remission in schizophrenic symptoms in a patient previously unresponsive to conventional treatment, according to a case report published in the Australian & New Zealand Journal of Psychiatry.

Investigators from the University of Leipzig in Germany assessed the use of twice-daily dosing of 750mg of CBD in conjunction with clozapine in a patient with treatment-resistant schizophrenia. Cannabidiol dosing was associated with remission criteria and improvements remained consistent over eight months.

“Our case report contradicts the assumption that CBD is not likely to be any superior than existing antipsychotics,” authors concluded. “In fact, CBD might be particularly suitable for those patients [who are] resistant to antipsychotics due to its different mode of action.”


For more information, contact Paul Armentano, NORML Deputy Director, at: paul@norml.org. Full text of the study, “Remission of severe, treatment-resistant schizophrenia following adjunctive cannabidiol,” appears in the Australian & New Zealand Journal of Psychiatry.

NIH: Teen Marijuana Use Not Increasing Despite Legalization

MARYLAND: Self-reported marijuana use by adolescents has failed to increase in recent years despite the majority of states legalizing it for either medical or adult use, according to the latest data compiled by the University of Michigan’s Monitoring the Future survey, which is commissioned by the US National Institutes on Drug Abuse. NIDA is a part of the US National Institutes of Health.

Summarizing the findings in a press release, the agency acknowledged: “Rates of marijuana use by teens have been of great interest to researchers over the past decade, given major social and legislative shifts around the drug; it is now legal for adult recreational use in 10 states plus the District of Columbia, and it is available medicinally in many more. Fortunately, even as teens’ attitudes toward marijuana’s harms continue to relax, they are not showing corresponding increases in marijuana use.”

Marijuana use prevalence by young people did not change significantly between 2017 and 2018, the survey reported. Between the years 2012 and 2018, both rates of lifetime marijuana use and rates of annual marijuana use by 8th, 10th, and 12th graders have declined. Ten states have enacted laws regulating adult marijuana use during this same period of time, and several others have legalized medical cannabis access.


For more information, contact Paul Armentano, NORML Deputy Director, at: paul@norml.org. Further data is available from NORML’s fact-sheet, “Marijuana Regulation and Teen Use Rates.”

 

Study: Long-Term Cannabis Use Not Associated With Changes In Brain Morphology

AUSTRALIA: The use of cannabis, even long-term, is not associated with changes in the cortical surface of the brain, according to data published in the journal European Neuropsychopharmacology.

A team of investigators from Australia and the Netherlands assessed the relationship between cannabis use and brain morphology in a cohort of 261 subjects (141 cannabis users and 120 controls). Researchers reported “no significant effects on cortical surface morphology” that could be attributable to subjects’ cannabis use, dependence, or age of initiation.

Authors concluded, “Our lack of finding in a well-powered study suggests that cortical surface morphology may be less associated with cannabis use than previously assumed.”

The findings are consistent with other recent brain imaging studies – such as those herehere, and here – and are largely inconsistent with those of a well-publicized 2014 study purporting that even causal cannabis exposure was linked to changes in the brain in young people.


For more information, contact Paul Armentano, NORML Deputy Director, at: paul@norml.org. Full text of the study, “Cortical surface morphology in long-term cannabis users: A multi-site MRI study,” appears in European Neuropsychopharmacology. Further information is available from the NORML fact-sheet, “Marijuana Exposure and Cognitive Performance.”

National Nursing Standards Legitimize Cannabis Nursing

Cannabis Nurses Network Steps in as Essential Resource for Medical Marijuana Education

CALIFORNIA: When the National Council of State Boards of Nursing released guidelines for cannabis patient care, it simultaneously validated the legitimacy of cannabis nursing, and underscored the immediate necessity for medical professionals to gain practical medical marijuana patient care education.

Cannabis Nurses Network, a professional education and development network, is producing the only conference where licensed medical professionals can get the education recommended in the NCSBN Guidelines; essential cannabis knowledge, clinical recommendations, administration and ethical considerations are integral to the programming. Cannabis Nurses Network Conference (CNNC) comes to San Diego, California February 28th-March 2nd, 2019.

February 28 – March 2, 2019 | San Diego, California

February 28 – March 2, 2019 | San Diego, California

“Cannabis Nurses are revolutionizing the future of plant-based healthcare. In response to a national shift that is currently occurring in healthcare, and specifically within the nursing profession, it has become imperative to provide nurses with access to high-level education involving the science, research, and implementation required for sustaining evidence-based practice regarding cannabis patients. CNN is heeding the call to deliver this important education during CNNC,” says the Founder of CNN and longtime advocate Heather Manus, RN.

National nursing guidelines and recommendations regarding cannabis related issues have recently been published highlighting required areas for nurses to seek continued education.

People are using legal cannabis products in nearly every state in our nation, with or without medical advice. Nurses are the patients’ lifeline, the heartbeat of healthcare, the ones who must learn and understand the importance of the human endocannabinoid system.


Nurses Network is stepping in as an international resource for cannabis patient care with the conference, and an online fundamentals curriculum addressing medical marijuana education, scheduled for release in early 2019. The Cannabis Nurses Network Conference offers accredited continuing education, while bringing together thought leaders, educators and authors in medical cannabis education to advance the quality of cannabis patient care around the globe.

420MEDIA has been named an official media partner for the Cannabis Nurses Network Conference.